HeyJaredMIB Agents OsteoBites and osTEAo
Each week, MIB Agents talks with the leaders and innovators in osteosarcoma surgery, research, treatment and advocacy. Questions are taken during the webinar and are included in each podcast. More information is available at www.mibagents.org
- Indexed episodes, last 90 days
- 11
- Latest publication
- Sep 29, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 16, 2026
Latest episodes
MISTOSUS: A phase II clinical trial of IscadorP (Mistletoe extract) as immunotherapy to improve event-free survival in patients with relapsed resectable osteosarcoma (opens the original)
Read excerpt
There is an urgent need for safe and effective therapies to improve outcomes for patients with relapsed osteosarcoma. Viscum album extract (Iscador P, Iscador AG, Arlesheim, Switzerland) is a mistletoe extract manufactured from the leaves, stems and berries of Viscum album L., grown on pine trees (P = Pini). It has shown efficacy and safety in lab experiments and small clinical trials for patients with relapsed osteosarcoma. Data from a small pilot study in Italy paved the way for developing a l
osTEAo: Let's Talk Childhood Cancer (opens the original)
Read excerpt
This month on osTEAo, Sammy, Inaaya, Mackenzie, and Keely discuss Childhood Cancer Awareness Month, how childhood cancer is portrayed and understood, and what those portrayals can miss about the realities of a cancer diagnosis. They share personal experiences and perspectives on awareness, treatment, advocacy, and the different ways patients, siblings, and families experience childhood cancer. They also reflect on the importance of supporting families who are grieving while continuing to raise a
A Phase 1b Study of Tegavivint, a TBL1 Inhibitor, with Gemcitabine in Patients with Relapsed or Refractory Osteosarcoma (TIGER) (opens the original)
Read excerpt
Osteosarcoma Webinar Series: W. Thomas Cash, MD, MSc Children's Healthcare of Atlanta will discuss his work the TIGER study, which is a phase 1 study testing the TBL1 inhibitor tegavivint in combination with gemcitabine for pediatric and AYA patients with relapsed or refractory osteosarcoma. The topic of this presentation is the TIGER study, which is a phase 1 study testing the TBL1 inhibitor tegavivint in combination with gemcitabine for pediatric and AYA patients with relapsed or refractory os
CCDI Data Ecosystem in Action: Enabling Data-Driven Discovery (opens the original)
Read excerpt
Osteosarcoma Webinar Series: Subhashini Jagu, PhD, from the National Cancer Institute, joins us on OsteoBites to discuss the Childhood Cancer Data Initiative. This presentation highlights how the Childhood Cancer Data Initiative (CCDI) Data Ecosystem is transforming pediatric cancer research by making diverse biomedical data more accessible, interoperable, and reusable. Attendees will learn how the CCDI Data Ecosystem connects distributed data resources, supports data discovery and sharing, and
Functional Precision Medicine for Osteosarcoma (opens the original)
Read excerpt
The Greenfield Lab’s long-standing research interests focus on basic and translational aspects of bone biology, and on osteosarcoma metastasis. The osteosarcoma project aims to repurpose FDA-approved drugs to block growth of lung metastases, which is the primary cause of lethality in osteosarcoma patients. Current studies utilize 3D sarcosphere cultures and mouse models. Dr. Greenfield earned his undergraduate degree in biology from New College of Florida and master’s and doctoral degrees in mar
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Not enough subject data for this period yet.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.